New and upcoming topical treatments for atopic dermatitis: a review of the literature
Abstract: Atopic dermatitis (AD) is a chronic inflammatory dermatosis with periods of exacerbation and remissions. AD is characterized by intense, persistent pruritus and heterogeneity in clinical symptomatology and severity. Therapeutic goals include the amelioration of cutaneous eruptions, diminishing relapses and eventually the disease burden. To date, topical corticosteroids (TCS) and calcineurin inhibitors (TCI) have yet been deemed the mainstay of topical treatments in AD management. Nevertheless, despite their indisputable efficiency, TCS and TCI are not indicated for continuous long-term use given their safety profile. While research in AD has concentrated predominantly on systemic therapies, more than 30 novel topical compounds are under development. The existing data appear encouraging, with some regimens that are already FDA-approved (ruxolitinib was the most recent in September 2021) and several pharmaceutical pipeline products for mild-to-moderate AD that are in an advanced stage of development, such as tapinarof, difamilast and roflumilast. Larger, long-term studies are still required to evaluate the efficacy and safety of these novel compounds in the long run and weigh their advantages over present treatments. In this review, we aim to provide an overview of the latest knowledge about AD topical treatments, echoing upcoming research trends
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Journal of clinical medicine. - 11, 17 (2022) , 4974, ISSN: 2077-0383
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2022
- Urheber
-
Sideris, Nikolaos
Paschou, Eleni
Bakirtzi, Katerina
Kiritsi, Dimitra
Papadimitriou, Ilias
Tsentemeidou, Aikaterini
Sotiriou, Elena
Vakirlis, Efstratios
- DOI
-
10.3390/jcm11174974
- URN
-
urn:nbn:de:bsz:25-freidok-2294188
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sideris, Nikolaos
- Paschou, Eleni
- Bakirtzi, Katerina
- Kiritsi, Dimitra
- Papadimitriou, Ilias
- Tsentemeidou, Aikaterini
- Sotiriou, Elena
- Vakirlis, Efstratios
- Universität
Entstanden
- 2022
Ähnliche Objekte (12)
Postzygotic mosaicism in genetic skin disorders : causes and pathogenetic mechanisms
Transmembrane collagens - unexplored mediators of epidermal‐dermal communication and tissue homeostasis
Tolerability of Topical Treatments for Atopic Dermatitis
Systemic retinoids for treatment of recalcitrant IgA pemphigus
Plectin in skin fragility disorders
Inborn errors of immunity and immunodeficiencies: Antibody‐mediated pathology and autoimmunity as a consequence of impaired immune reactions
Recent advances in understanding and managing epidermolysis bullosa
Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa
Dupilumab zur Behandlung der Epidermolysis bullosa acquisita
Case report: minimal manifestations of mucous membrane pemphigoid in a young adult
Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers
Treatment of Epidermolysis bullosa acquisita with dupilumab
Postzygotic mosaicism in genetic skin disorders : causes and pathogenetic mechanisms
Transmembrane collagens - unexplored mediators of epidermal‐dermal communication and tissue homeostasis
Tolerability of Topical Treatments for Atopic Dermatitis
Systemic retinoids for treatment of recalcitrant IgA pemphigus
Plectin in skin fragility disorders
Inborn errors of immunity and immunodeficiencies: Antibody‐mediated pathology and autoimmunity as a consequence of impaired immune reactions
Recent advances in understanding and managing epidermolysis bullosa
Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa
Dupilumab zur Behandlung der Epidermolysis bullosa acquisita
Case report: minimal manifestations of mucous membrane pemphigoid in a young adult
Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers
Treatment of Epidermolysis bullosa acquisita with dupilumab
Postzygotic mosaicism in genetic skin disorders : causes and pathogenetic mechanisms
Transmembrane collagens - unexplored mediators of epidermal‐dermal communication and tissue homeostasis
Tolerability of Topical Treatments for Atopic Dermatitis
Systemic retinoids for treatment of recalcitrant IgA pemphigus
Plectin in skin fragility disorders
Inborn errors of immunity and immunodeficiencies: Antibody‐mediated pathology and autoimmunity as a consequence of impaired immune reactions
Recent advances in understanding and managing epidermolysis bullosa
Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa
Dupilumab zur Behandlung der Epidermolysis bullosa acquisita
Case report: minimal manifestations of mucous membrane pemphigoid in a young adult
Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers